Aequus Pharmaceuticals Inc Total Liabilities
Aequus Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has total liabilities worth CA$7.09 Million CAD (≈ $5.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Aequus Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Aequus Pharmaceuticals Inc (2013–2024)
Total liabilities of Aequus Pharmaceuticals Inc from 2013 to 2024. This chart illustrates how Aequus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Aequus Pharmaceuticals Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Aequus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Christie Group plc
LSE:CTG
|
UK | GBX24.79 Million |
|
Craven House Capital PLC
LSE:CRV
|
UK | $1.93 Million |
|
Nulegacy Gold Corporation
V:NUG
|
Canada | CA$565.65K |
|
STMicroelectronics NV
LSE:0INB
|
UK | €7.83 Billion |
|
Lendinvest PLC
LSE:LINV
|
UK | GBX766.10 Million |
|
Goldplat PLC
LSE:GDP
|
UK | GBX16.02 Million |
|
Powell Max Limited Class A Ordinary Shares
NASDAQ:PMAX
|
USA | $17.46 Million |
|
Zapp Electric Vehicles Group Limited Ordinary Shares
NASDAQ:ZAPP
|
USA | $27.91 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Aequus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Aequus Pharmaceuticals Inc total assets.
Liquidity & Leverage Metrics
Aequus Pharmaceuticals Inc Total Liabilities Ratios Explained
Aequus Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 36.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aequus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aequus Pharmaceuticals Inc (2013–2024)
The table below shows the annual total liabilities of Aequus Pharmaceuticals Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$7.26 Million ≈ $5.25 Million |
+34.85% |
| 2023-12-31 | CA$5.38 Million ≈ $3.89 Million |
+75.16% |
| 2022-12-31 | CA$3.07 Million ≈ $2.22 Million |
+20.03% |
| 2021-12-31 | CA$2.56 Million ≈ $1.85 Million |
-0.07% |
| 2020-12-31 | CA$2.56 Million ≈ $1.85 Million |
+0.43% |
| 2019-12-31 | CA$2.55 Million ≈ $1.84 Million |
+709.71% |
| 2018-12-31 | CA$314.90K ≈ $227.79K |
-14.16% |
| 2017-12-31 | CA$366.84K ≈ $265.36K |
-50.72% |
| 2016-12-31 | CA$744.41K ≈ $538.50K |
-34.99% |
| 2015-12-31 | CA$1.15 Million ≈ $828.33K |
+53.80% |
| 2014-12-31 | CA$744.51K ≈ $538.56K |
+1212.23% |
| 2013-12-31 | CA$56.74K ≈ $41.04K |
-- |
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more